Avene, a brand of French pharmaceutical and cosmetics company Pierre Fabre Laboratories, announced on Wednesday a breakthrough in the field of clinical studies in dermo-cosmetics in partnership with healthtech company BotDesign.

In 2026, Avene plans to conduct a comparative clinical study to evaluate the efficacy of its new treatment for acne-prone skin, Avene Cleanance Comedomed+, in the maintenance phase following oral isotretinoin treatment in adults suffering from severe to very severe acne.

According to Pierre Fabre Laboratories, Avene will become the first brand to use artificial intelligence in clinical studies for dermo-cosmetics.

Dr. Gautier Doat, Eau Thermale Avene medical director, said: "We belong to a group that has always been rooted in pharmaceuticals and dermo-cosmetics. Our medical expertise gives us a head start in understanding patients and their pathologies. We are ideally positioned to offer treatment protocols based on the pathology, combining dermo-cosmetics with medication. We are already preparing solutions to go further, by developing dermo-cosmetic innovations capable of extending and amplifying the action of the medication or delaying its necessity. Because these are dermo-cosmetics, they can be used over the long term, unlike many drug treatments."